Abdera Therapeutics’ Post

#EMEA physicians, check out this Interventional News article! Industry experts share insights from the SUMM90YT conference in Germany, walking through the efficacy and flexibility of #SIRT with SIR-Spheres. https://lnkd.in/ek_7fMhv

𝐓𝐡𝐞 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐢𝐬 𝐚𝐛𝐮𝐳𝐳 𝐰𝐢𝐭𝐡 𝐠𝐫𝐨𝐮𝐧𝐝𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬, 𝐚𝐧𝐝 𝐰𝐞'𝐯𝐞 𝐠𝐨𝐭 𝐭𝐡𝐞 𝐬𝐜𝐨𝐨𝐩❗ 𝐓𝐨𝐝𝐚𝐲'𝐬 𝐡𝐞𝐚𝐝𝐥𝐢𝐧𝐞𝐬 𝐚𝐫𝐞: 1. OMRON Group acquires Dutch Luscii - an OMRON Healthcare service: Expanding reach in European market 2. Indian diagnostic equipment market set to reach $6 Billion by 2027 3. CDSCO FDA India MoHFW approves ErlySign's Oral Cancer Detection Technology for large-scale clinical trials 4. Gleneagles Hospitals, India inaugurates advanced Bi-Plane cath lab for quicker diagnosis and safety   𝐂𝐥𝐢𝐜𝐤 𝐨𝐧 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐧𝐭 𝐬𝐞𝐜𝐭𝐢𝐨𝐧 𝐭𝐨 𝐰𝐚𝐭𝐜𝐡 𝐭𝐡𝐞 𝐧𝐞𝐰𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐧𝐨𝐰❗   #medicalindustry #healthcareinnovation #omron #lusciihealthtech #erlysign #gleneagleshospital

Join us for an upcoming webinar 👉 Locate and Track: ctDNA Monitoring in NSCLC with Signatera, featuring Dr. Leo Shunyakov and Dr. Michael Krainock, discussing the following data: 🧬 EMPower Lung-1 trial: Demonstrating early on-treatment ctDNA dynamics were predictive of OS in 1L metastatic patients treated with immunotherapy 🧬 MSKCC Unresectable NSCLC study: Showing Signatera’s ability to risk-stratify and detect recurrences early in unresectable NSCLC patients treated with radiotherapy +/- consolidation immunotherapy 🧬 Baylor University Resectable NSCLC study: Demonstrating how post-operative ctDNA detection was highly prognostic of recurrence with significant lead time vs imaging Register below. https://ow.ly/VNv650Q2PtL

Delving into the Future of Medicine: Next-Gen Antibody-Drug Conjugates Exciting strides are being made in the realm of medicine! 🚀 Researchers are exploring the potential of next-generation antibody-drug conjugates, aiming to revolutionize treatment modalities and enhance patient outcomes. Dive into the latest findings and discoveries in this groundbreaking field! 💉🔬 #MedicalInnovation #DrugDevelopment #ResearchAdvancements Read more: https://lnkd.in/dGCM_Sv2

New article from the Journal of Comparative Effectiveness Research, partner publication to The Evidence Base® In #CancerResearch, #RealWorldData can provide #externalcontrolarms (#ECAs) for #singlearmtrials. But are ECAs fit-for-purpose when comparing treatments? We show how historical trials and #BayesianBorrowing might be used to increase confidence in ECAs. Authors: Alessandria Strübing (Daiichi Sankyo Europe GmbH), Chelsea M. (Cytel), Haoyao Ruan (Cytel), Emma Mackay, Natalie Dennis (Daiichi Sankyo), Russanthy R. Velummailum (Cytel), Philip He (Daiichi Sankyo US), Yoko T. (Daiichi Sankyo), Yan Xiong (Daiichi Sankyo), Aaron Springford and Mats Rosenlund (Daiichi Sankyo Europe). #rwd #hta #healthtechnologyassessment

Thank you Jesus! 🚀 Delighted to announce the publication of our groundbreaking article titled "The Promise of RNA-Based Therapeutics in Revolutionizing Heart Failure Management"! In this comprehensive narrative review, we explored the immense potential of RNA-based therapeutics to revolutionize the landscape of heart failure management. Through a meticulous analysis of current evidence, we uncover exciting prospects in personalized treatment strategies, targeted modulation of molecular pathways, and the power of combination therapies to achieve synergistic effects. Our research delves into the regenerative capacity of RNA-based therapeutics for cardiac repair, opening new avenues for enhanced patient outcomes. 💓 Moreover, we shed light on the inherent advantages associated with noninvasive routes of administration, further elevating the promise of these novel interventions. As we move towards a future of innovative medical advancements, diligent monitoring of disease progression and treatment response remains pivotal to ensuring patient safety and long-term success. This article serves as a vital resource for understanding the fast-moving realm of RNA-based therapies, offering a beacon of hope for improved heart failure management. Gratitude to our dedicated team and collaborators for their unwavering commitment to advancing medical research. Access article here: https://lnkd.in/dTfq_cBh #MedicalResearch #HeartFailureManagement #RNABasedTherapeutics #Innovation #PersonalizedMedicine #RegenerativeMedicine #HealthcareAdvancements #ResearchArticle #MedicalScience #TransformativeTherapies

In the ever-evolving landscape of CAR T cell therapies, what are the best practices for overcoming challenges related to (1) monitoring CAR T cells, (2) ensuring patient safety, and (3) assessing the therapy response? Our experts Goran Marinković, Ph.D. Karthikeyan Devaraju, nele langenaken and Nithianandan Selliah, Ph.D will dive deeper into this questions and guide you along the way! Register here: https://lnkd.in/eGrhq-2b

It will be a great webinar on CAR T cells.